Evidence map›Paper›PMID 34869253›Full record

ArticleFrontiers in bioengineering and biotechnology2021

An ECHO of Cartilage:

Sakshi Khurana, Stefano Schivo, Jacqueline R M Plass, Nikolas Mersinis, Jetse Scholma, Johan Kerkhofs, Leilei Zhong, Jaco van de Pol, Rom Langerak, Liesbet Geris and 2 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in bioengineering and biotechnology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 3 countries.

Sakshi KhuranaTechnical Medicine Centre, Department of Developmental BioEngineering, University of Twente, Enschede, Netherlands.
Stefano SchivoTechnical Medicine Centre, Department of Developmental BioEngineering, University of Twente, Enschede, Netherlands.
Jacqueline R M PlassTechnical Medicine Centre, Department of Developmental BioEngineering, University of Twente, Enschede, Netherlands.
Nikolas MersinisTechnical Medicine Centre, Department of Developmental BioEngineering, University of Twente, Enschede, Netherlands.
Jetse ScholmaTechnical Medicine Centre, Department of Developmental BioEngineering, University of Twente, Enschede, Netherlands.
Johan KerkhofsBiomechanics Research Unit, GIGA In Silico Medicine, ULiège, Liège, Belgium.
Leilei ZhongTechnical Medicine Centre, Department of Developmental BioEngineering, University of Twente, Enschede, Netherlands.
Jaco van de PolDepartment of Formal Methods and Tools, CTIT Institute, University of Twente, Enschede, Netherlands.
Rom LangerakDepartment of Formal Methods and Tools, CTIT Institute, University of Twente, Enschede, Netherlands.
Liesbet GerisBiomechanics Section, Department of Mechanical Engineering, KU Leuven, Leuven, Belgium.
Marcel KarperienTechnical Medicine Centre, Department of Developmental BioEngineering, University of Twente, Enschede, Netherlands.
Janine N PostTechnical Medicine Centre, Department of Developmental BioEngineering, University of Twente, Enschede, Netherlands.
University of Twente · NLKU Leuven · BEUniversity of Liège · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A fundamental question in cartilage biology is: what determines the switch between permanent cartilage found in the articular joints and transient hypertrophic cartilage that functions as a template for bone? This switch is observed both in a subset of OA patients that develop osteophytes, as well as in cell-based tissue engineering strategies for joint repair. A thorough understanding of the mechanisms regulating cell fate provides opportunities for treatment of cartilage disease and tissue engineering strategies. The objective of this study was to understand the mechanisms that regulate the switch between permanent and transient cartilage using a computational model of chondrocytes, ECHO. To investigate large signaling networks that regulate cell fate decisions, we developed the software tool ANIMO, Analysis of Networks with interactive Modeling. In ANIMO, we generated an activity network integrating 7 signal transduction pathways resulting in a network containing over 50 proteins with 200 interactions. We called this model ECHO, for executable chondrocyte. Previously, we showed that ECHO could be used to characterize mechanisms of cell fate decisions. ECHO was first developed based on a Boolean model of growth plate. Here, we show how the growth plate Boolean model was translated to ANIMO and how we adapted the topology and parameters to generate an articular cartilage model. In ANIMO, many combinations of overactivation/knockout were tested that result in a switch between permanent cartilage (SOX9+) and transient, hypertrophic cartilage (RUNX2+). We used model checking to prioritize combination treatments for wet-lab validation. Three combinatorial treatments were chosen and tested on metatarsals from 1-day old rat pups that were treated for 6 days. We found that a combination of IGF1 with inhibition of ERK1/2 had a positive effect on cartilage formation and growth, whereas activation of DLX5 combined with inhibition of PKA had a negative effect on cartilage formation and growth and resulted in increased cartilage hypertrophy. We show that our model describes cartilage formation, and that model checking can aid in choosing and prioritizing combinatorial treatments that interfere with normal cartilage development. Here we show that combinatorial treatments induce changes in the zonal distribution of cartilage, indication possible switches in cell fate. This indicates that simulations in ECHO aid in describing pathologies in which switches between cell fates are observed, such as OA.

Indexed as

BMP7chondrogenesiscomputational modelhypertrophyIGFPTHrPsignal transduction

Identifiers

PMID34869253
PMCPMC8634894
OpenAlexW3213530447

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.